CANBRIDGE PHARM.DL-00001 Tangible Net Worth Ratio
CANBRIDGE PHARM.DL-00001 tangible net worth ratio. CANBRIDGE PHARM.DL-00001 (MF1) has a Tangible Net Worth Ratio of 77.9% as of December 2022. This metric is calculated by deducting intangible assets (€68.13 Million) from net assets (€308.56 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See MF1 net asset quality score to measure how much of total assets are equity-financed.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of CANBRIDGE PHARM.DL-00001 (2021–2022)
Tangible net worth ratio of CANBRIDGE PHARM.DL-00001 from 2021 to 2022. This chart shows how CANBRIDGE PHARM.DL-00001's Tangible Net Worth Ratio has changed across 2 annual periods from 2021 to 2022. As of December 2022, the ratio stands at 77.9%, reflecting net assets of €308.56 Million with intangible assets of €68.13 Million EUR. See CANBRIDGE PHARM.DL-00001 (MF1) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
CANBRIDGE PHARM.DL-00001 Tangible Net Worth Ratio by Year (2021–2022)
CANBRIDGE PHARM.DL-00001 tangible net worth ratio by year from 2021 to 2022. The table below presents the year-by-year Tangible Net Worth Ratio for CANBRIDGE PHARM.DL-00001 from 2021 to 2022, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see market cap of CANBRIDGE PHARM.DL-00001.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2022 | 77.9% | €308.56 Million | €68.13 Million | €702.04 Million | ▼ -14.7 pp |
| 2021 | 92.6% | €693.39 Million | €51.27 Million | €892.52 Million | — |